Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Interim Results

26 Jan 2006 08:23

Readybuy PLC26 January 2006 Readybuy Plc Interim Announcement for the six months ended 31 October 2005 Chairman's Statement The results for the six months to 31 October show a loss of £85,000. Thisreflects the costs of closure of the manufacturing facility and also atermination payment to the former Chief Executive. The group has now exited completely from chilled food manufacturing. The ongoing costs are now minimal as the board seeks to preserve as much cash aspossible. We continue to explore a number of opportunities and I hope to be ableto announce some progress in the near future. Colin Davies Chairman READYBUY PLCGROUP PROFIT AND LOSS ACCOUNTfor the six months to 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 Notes £'000 £'000 £'000 Turnover 4 313 139 ______ ______ ______ Operating loss (84) (252) (137) Provision for loss on operations to be discontinued - (804) - ______ ______ ______ Loss on ordinary activities before interest (84) (1,056) (137) Net interest (1) (2) (1) ______ ______ ______ Loss before taxation (85) (1,058) (138) Taxation - (45) - ______ ______ ______ Loss after taxation (85) (1,103) (138) Dividends - - - ______ ______ ______ Retained loss (85) (1,103) (138) ______ ______ ______ ---------- ----------- ---------- Loss per shareBasic and diluted 3 (0.4)p (6.1)p (0.8)p Dividends per share - - - The group's trading activities were terminated in July 2005, therefore all ofthe above activities are classified as discontinued. READYBUY PLCGROUP BALANCE SHEETat 31 October 2005 Unaudited Audited Unaudited 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Fixed assets Goodwill - - 629 Tangible assets - - 208 ______ ______ ______ - - 837 Current assetsStock - 2 17 Debtors 3 44 116Cash at bank 38 169 276 ______ ______ ______ 41 215 409 ______ ______ ______ Creditors falling due within one year (5) (194) (334) ______ ______ ______ Net current assets 36 21 75 ______ ______ ______ Total assets less current liabilities 36 21 912 Creditors falling due after one year - - (16) ______ ______ ______ 36 21 896 ______ ______ ______ ----------- ---------- ---------- Capital and reservesCalled up share capital 97 93 90Share premium account 1,425 1,329 1,242Profit and loss account (1,486) (1,401) (436) ______ ______ ______ Equity shareholders' funds 36 21 896 ______ ______ ______ ----------- ---------- ---------- READYBUY PLC GROUP CASHFLOW STATEMENT for the six months ended 31 October 2005 Unaudited Audited Unaudited 6 months to Year to 6 months to 31/10/2005 30/04/2005 31/10/2004 £'000 £'000 £'000 Operating loss (84) (252) (137) Gain on sale of fixed assets (25) - - Depreciation and amortisation - 67 33 Movement in working capital (21) 105 (17) Net cash outflow from operating activities (130) (80) (121) Net cash outflow from servicing of finance (1) (2) - Net cash inflow/(outflow) from capital expenditure and 25 (8) (6) financial investment Net cash outflow before use of liquid resources and financing (106) (90) (127) Capital element of finance lease payments (25) (34) (25) Repayment of convertible loans (100) - - Issue of ordinary share capital net of redemption 100 90 - Net cash (outflow)/inflow from financing (25) 56 (25) Decrease in cash in the period (131) (34) (152) Analysis of net funds Cash at bank and in hand 38 169 276 Overdraft - - (225) 38 169 51 Debt repayable by instalments: Due within one year - (25) (18) Due after more than one year - - (16) 38 (25) (34) 38 144 17 READYBUY PLCINTERIM ACCOUNTSfor the six months to 31 October 2005 Notes 1 The unaudited results for the six month period have been prepared on a basis consistent with the accounting policies disclosed in the Group's 2005 accounts and do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. 2 The figures for the period ended 30 April 2005 have been extracted from the statutory accounts which have been delivered to the Registrar of Companies and received an unqualified audit report. 3 The calculation of earnings per share for the period is based on the loss after taxation divided by the average number of ordinary shares in issue, being 19,240,387 (31 October 2004 - 17,994,010 and period ended 30 April 2005 - 18,066,870). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Sep 20177:00 amRNSNotice of Results
21st Aug 201712:00 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSTrading Update
31st Jul 201712:00 pmRNSIssue of Equity
28th Jul 20171:15 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSDirector Dealing and Issue of Equity
4th Jul 20177:00 amRNSManchester ShareSoc Growth Company Seminar
5th Jun 20177:00 amRNSShareSoc Growth Company Seminar
1st Jun 20178:56 amRNSIssue of Equity
22nd May 20177:00 amRNS2 Biotech's Licence Affimers for Research Use
10th May 20177:00 amRNSKey Affimer Patent To Be Granted in China
8th May 20171:21 pmRNSHardman Research: De-risking Moderna's partnership
5th May 20177:00 amRNSPresenting at the Hardman Private Investor Forum
2nd May 20177:00 amRNSAvacta to Present at BioTrinity 2017
24th Apr 20177:00 amRNSDiagnostics firm take rights to several Affimers
19th Apr 20177:00 amRNSAvacta to Present at the Shares Spotlight Evening
12th Apr 20177:15 amRNSHardman Research: Another important box ticked
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 201710:22 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSInterim Results for the Period Ended 31 Jan 2017
3rd Apr 20177:00 amRNSResults of Immunogenicity Study with Human Samples
31st Mar 20179:31 amRNSAvacta Presents at Investor Evening Hosted by TPI
31st Mar 20177:00 amRNSLondon Growth and Innovation Forum Presentation
22nd Mar 20179:00 amRNSAvacta to present at the UK Investor Show
21st Mar 20177:15 amRNSHardman Research: Low response would be positive!
30th Jan 20177:00 amRNSDirector/PDMR Shareholding
20th Jan 201711:35 amRNSResult of Annual General Meeting
20th Jan 20177:00 amRNSTrading Update
11th Jan 20177:00 amRNSPresenting at London Growth and Innovation Forum
5th Jan 20177:00 amRNSDirector Dealing and Issue of Equity
20th Dec 20167:00 amRNSDirector/PDMR Shareholding
16th Dec 20165:14 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSNotice of AGM, Accounts and Directorate Change
23rd Nov 20167:00 amRNSTechnical Update: Affinity Separation
7th Nov 20167:00 amRNSCancer Expert joins Scientific Advisory Board
2nd Nov 20167:00 amRNSCAR-T Cell Therapy Research Collaboration in US
1st Nov 20167:00 amRNSResults from first Affimer pre-clinical studies
21st Oct 201611:39 amRNSDirector's Dealing
17th Oct 20161:00 pmRNSHardman Research: Great strides to strategic goals
17th Oct 20167:00 amRNSPrelim Results for the Year Ended 31 July 2016
4th Oct 20163:28 pmRNSIssue of Equity
26th Sep 201611:21 amRNSNotice of Results
22nd Sep 20167:00 amRNSPositive results from first preclinical studies
12th Sep 20167:00 amRNSChange of Adviser
31st Aug 20162:17 pmRNSChange of Registered Office
16th Aug 20167:00 amRNSNew Facilities in Cambridge and Wetherby
10th Aug 20167:00 amRNSGrant Funding
3rd Aug 20167:00 amRNSKey Affimer patents to be granted in Europe and US
1st Aug 20167:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.